P2X Purinoceptor 3 - Pipeline Review, H1 2020

June 2020 | 67 pages | ID: PF99C9907E63EN
Global Markets Direct

Abstracts

P2X Purinoceptor 3 - Pipeline Review, H1 2020

SUMMARY

According to the recently published report 'P2X Purinoceptor 3 – Pipeline Review, H1 2020'; P2X Purinoceptor 3 (P2RX3) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes.

P2X Purinoceptor 3 (P2RX3) – P2X purinoceptor 3 is a protein encoded by the P2RX3 gene. It belongs to the family of purinoceptors. This receptor functions as a ligand-gated ion channel and transduce ATP-evoked nociceptor activation. This receptor is important for peripheral pain responses, and also participates in pathways controlling urinary bladder volume reflexes.

The report 'P2X Purinoceptor 3 – Pipeline Review, H1 2020' outlays comprehensive information on the P2X Purinoceptor 3 (P2RX3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 4, 5 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecule, respectively. Report covers products from therapy areas Central Nervous System, Respiratory, Dermatology, Genito Urinary System And Sex Hormones, Ophthalmology and Women's Health which include indications Chronic Cough, Pain, Neuropathic Pain (Neuralgia), Cough, Inflammatory Pain, Pruritus, Visceral Pain, Alzheimer's Disease, Endometriosis, Insomnia, Obstructive Sleep Apnea, Ocular Hypertension, Open-Angle Glaucoma, Overactive Bladder and Sleep Apnea.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The report provides a snapshot of the global therapeutic landscape for P2X Purinoceptor 3 (P2RX3)
• The report reviews P2X Purinoceptor 3 (P2RX3) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in P2X Purinoceptor 3 (P2RX3) targeted therapeutics and enlists all their major and minor projects
• The report assesses P2X Purinoceptor 3 (P2RX3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to P2X Purinoceptor 3 (P2RX3) targeted therapeutics

REASONS TO BUY

• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for P2X Purinoceptor 3 (P2RX3)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding P2X Purinoceptor 3 (P2RX3) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Contents

Introduction
Global Markets Direct Report Coverage
P2X Purinoceptor 3 (P2RX3) - Overview
P2X Purinoceptor 3 (P2RX3) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
P2X Purinoceptor 3 (P2RX3) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
P2X Purinoceptor 3 (P2RX3) - Companies Involved in Therapeutics Development
Asana BioSciences LLC
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
BELLUS Health Inc
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Pfizer Inc
Shionogi & Co Ltd
P2X Purinoceptor 3 (P2RX3) - Drug Profiles
ASN-009 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BAY-1817080 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-5937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
gefapixant citrate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibodies to Antagonize P2X3 Receptor for Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Antagonize P2X2 and P2X3 for Visceral Pain - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P2X Purinoceptor 3 (P2RX3) - Dormant Products
P2X Purinoceptor 3 (P2RX3) - Discontinued Products
P2X Purinoceptor 3 (P2RX3) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020 (Contd..1), H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Asana BioSciences LLC, H1 2020
Pipeline by Bayer AG, H1 2020
Pipeline by Beijing Tide Pharmaceutical Co Ltd, H1 2020
Pipeline by BELLUS Health Inc, H1 2020
Pipeline by Integral Molecular Inc, H1 2020
Pipeline by Merck & Co Inc, H1 2020
Pipeline by Neurim Pharmaceuticals Ltd, H1 2020
Pipeline by Ossianix Inc, H1 2020
Pipeline by Pfizer Inc, H1 2020
Pipeline by Shionogi & Co Ltd, H1 2020
Dormant Products, H1 2020
Dormant Products, H1 2020 (Contd..1), H1 2020
Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Molecule Types, H1 2020
Number of Products by Stage and Molecule Types, H1 2020

COMPANIES MENTIONED

Asana BioSciences LLC
Bayer AG
Beijing Tide Pharmaceutical Co Ltd
BELLUS Health Inc
Integral Molecular Inc
Merck & Co Inc
Neurim Pharmaceuticals Ltd
Ossianix Inc
Pfizer Inc
Shionogi & Co Ltd